Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) began an underwritten public offering of approximately $200.0 million of common stock and pre-funded warrants. All securities are offered by the company, with underwriters granted a 30-day option to buy up to an additional 15% of the shares. The deal is subject to market conditions and will be issued under an effective shelf registration filed in November 2025.

Positive

• Planned equity and warrant offering targeting approximately $200.0 million in gross proceeds
• 30-day underwriter option to purchase up to an additional 15% of shares
• Use of an effective shelf registration may streamline capital-raising process

Negative

• New common stock and pre-funded warrants imply potential dilution for existing TSHA shareholders
• Underwriter option for up to 15% additional shares could further increase dilution
• Offering size and terms remain subject to market conditions and may not be completed

News Market Reaction – TSHA

-10.52%

4 alerts

-10.52% Session close to close

-6.9% Trough Tracked

$1.99B Market Cap

0.1x Rel. Volume

In the Jun 25 session, TSHA declined 10.52%, reflecting a significant negative market reaction. Argus tracked a trough of -6.9% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -10.5% in the session following this news. A negative reaction despite positive re...

Analysis

The stock dropped -10.5% in the session following this news. A negative reaction despite positive recent clinical progress fits TSHA’s pattern of sharp moves around financing, with past offering news averaging about -2%. Elevated short positioning and prior insider selling may amplify downside if dilution fears dominate.

Key Figures

Proposed offering size: $200.0 million Underwriter option window: 30 days Underwriter overallotment: 15% additional shares

3 metrics

Proposed offering size $200.0 million Underwritten public offering of common stock and pre-funded warrants

Underwriter option window 30 days Period for underwriters’ option to buy up to 15% additional shares

Underwriter overallotment 15% additional shares Potential extra common shares, including those underlying pre-funded warrants

Previous Offering Reports

4 past events · Latest: May 28 (Negative)

Same Type Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
May 28	Offering pricing	Negative	+12.7%	Pricing of large stock and pre-funded warrant offering with ~$200M gross proceeds.
May 28	Offering proposal	Negative	+12.7%	Announcement of proposed public offering with 15% underwriter option under shelf.
Jun 26	Offering pricing	Negative	-17.2%	Pricing of $75M stock and pre-funded warrant offering with underwriter option.
Jun 25	Offering proposal	Negative	-17.2%	Proposed $75M public offering and 15% underwriter option under existing shelf.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historically, TSHA’s equity offerings have produced mixed reactions, with both sharp gains and sharp losses following pricing or proposal announcements.

Key Terms

pre-funded warrants, underwritten public offering, shelf registration statement, prospectus supplement

4 terms

pre-funded warrants financial

"in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

"today announced that it has commenced an underwritten public offering of $200.0 million"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"A shelf registration statement relating to the securities offered in the public offering described above was filed"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of $200.0 million shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions (including shares underlying the pre-funded warrants). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Jefferies, Goldman Sachs & Co. LLC, Piper Sandler and Cantor are acting as joint book-running managers for the proposed offering. Baird is acting as lead manager for the proposed offering.

A shelf registration statement relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the SEC) on November 4, 2025, and became automatically effective upon filing. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, or by email at prospectus@psc.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of TSHA-102 and Taysha’s other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha’s research, development and regulatory plans for its product candidates and Taysha’s anticipated public offering, including the uncertainties related to market conditions and the completion of the public offering on the anticipated terms, if at all. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha’s business are described in detail in its SEC filings, including in Taysha’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law.

Company Contact:  
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com 

Media Contact: 
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com 

FAQ

What did Taysha Gene Therapies (TSHA) announce on June 24, 2026?

Taysha Gene Therapies announced a proposed underwritten public offering of approximately $200.0 million in common stock and pre-funded warrants. According to the company, all securities are being offered by Taysha under an effective shelf registration statement.

How large is the proposed TSHA stock and pre-funded warrant offering?

The proposed TSHA offering targets approximately $200.0 million of common stock and pre-funded warrants. According to Taysha, the exact size and final terms may change, as the transaction is subject to market conditions and may not be completed.

What is the 30-day underwriter option in the Taysha (TSHA) 2026 offering?

Taysha intends to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares. According to the company, this option also covers shares underlying the pre-funded warrants, under the same terms and conditions.

What type of securities is Taysha Gene Therapies (TSHA) offering in 2026?

Taysha plans to offer shares of common stock and pre-funded warrants to purchase common stock. According to the company, certain investors may opt for pre-funded warrants instead of common shares within this underwritten public offering structure.

Who are the joint book-running managers for the 2026 TSHA public offering?

Jefferies, Goldman Sachs & Co. LLC, Piper Sandler and Cantor are joint book-running managers. According to Taysha, Baird will act as lead manager, and the transaction will be made only through a prospectus and prospectus supplement.

Is the Taysha Gene Therapies (TSHA) 2026 offering guaranteed to be completed?

The TSHA offering is not guaranteed to be completed. According to Taysha, the transaction is subject to market conditions, and there can be no assurance regarding completion timing, actual size, or final terms of the offering.

Where can investors find the prospectus for the Taysha (TSHA) 2026 stock offering?

Investors can access the preliminary prospectus supplement and prospectus on the SEC website. According to Taysha, copies may also be obtained from Jefferies, Goldman Sachs, Piper Sandler, or Cantor using the contact details provided in the announcement.